US Patent

US7572789 — Salts of potassium ATP channel openers and uses thereof

Composition of Matter · Assigned to Essentialis Inc · Expires 2026-12-20 · 1y remaining

Vulnerability score 35/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects salts of potassium ATP channel openers, including diazoxide, and their pharmaceutical formulations and methods of administration.

USPTO Abstract

Provided are immediate or prolonged administration of certain salts of K ATP channel openers such as diazoxide to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic and compositional outcomes in the treatment of diseases or conditions involving K ATP channels. Also provided are pharmaceutical formulations, methods of administration and dosing of the salts that achieve these outcomes and reduce the incidence of adverse effects in treated individuals. Further provided are method of co-administering the salts with other drugs to treat diseases of humans and animals.

Drugs covered by this patent

Patent Metadata

Patent number
US7572789
Jurisdiction
US
Classification
Composition of Matter
Expires
2026-12-20
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Essentialis Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.